Dehydrocholesterol Reductase 24 (DHCR24): Medicinal Chemistry, Pharmacology and Novel Therapeutic Options.
Level 5 - mechanism / opinion, no new human data
Narrative review of medicinal chemistry and mechanism with no new human data
PubMed 34781860 · doi:10.2174/0929867328666211115121832
What was done
This is a narrative review summarizing the medicinal chemistry, pharmacology, and therapeutic potential of dehydrocholesterol reductase 24 (DHCR24) inhibition. The authors describe the molecular mechanisms linking DHCR24 inhibition to liver X receptor (LXR) activation and survey steroidal (e.g., 20,25-diazacholesterol, SH42) and nonsteroidal (e.g., amiodarone, triparanol) inhibitor lead structures.
What was found
The abstract reports no quantitative results or empirical trial data. It details the mechanism by which DHCR24 inhibition drives accumulation of desmosterol (an endogenous LXR agonist), proposing this indirect pathway as a means to activate LXR without activating sterol-response element binding proteins (SREBP) and stimulating lipogenesis.
Why it matters
Direct synthetic LXR agonists have been limited in clinical translation due to adverse lipid synthesis; indirect activation via DHCR24 inhibition provides an alternative therapeutic avenue for metabolic, inflammatory, and infectious diseases.
Limits
No human clinical data, quantitative outcome measures, or systematic search methodologies are reported in the abstract. Therapeutic efficacy and safety profiles remain preclinical and conceptual.
Cited by
- supports Triparanol, approved in the 1950s/1960s to lower cholesterol, worked by inhibiting the enzyme converting desmosterol to cholesterol, which caused desmosterol accumulation and increased heart attacks.